Combination Therapy Improves HER2-Positive Cancer Survival

Adults with advanced gastroesophageal cancer may see improved survival with a new combination drug regimen approved for use.

Updated on Oct. 23, 2026 in Cancer

Three clear glass medical vials with translucent liquid arranged on a metallic surface in a clinical laboratory. — A new combination therapy involving Tevimbra and Ziihera alongside chemotherapy has received U.S. approval for treating HER2-positive gastroesophageal adenocarcinoma. AI Illustration. Upload story photo >

Live Poll

Do you trust that new pharmaceutical clinical study results accurately predict long-term patient outcomes?

A Phase 3 study shows that combining the medications Tevimbra and Ziihera with chemotherapy improved survival outcomes for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. This treatment option was granted U.S. approval in August 2026.

Why it matters

Gastroesophageal adenocarcinoma remains difficult to treat, and this combination therapy provides a new approach to extending life for patients with HER2-positive disease. The results help clarify how adding these specific agents to standard chemotherapy may impact survival outcomes across different tumor profiles.

This Phase 3 trial evaluated overall survival in patients with HER2-positive gastroesophageal adenocarcinoma, showing a median survival of 27 months for the Tevimbra and Ziihera combination compared to 22.9 months for the Ziihera-only regimen.

The players

BeOne Medicines

A pharmaceutical company focused on developing novel oncology treatments, including targeted therapies for gastroesophageal cancers.

The details

The treatment works by incorporating targeted agents into a chemotherapy regimen to address HER2-positive cancer cells regardless of PD-L1 status. By combining these therapies, the researchers aimed to increase the body's ability to inhibit cancer cell growth compared to using chemotherapy alongside the standard drug trastuzumab. The study measured survival outcomes over a three-year period to assess the efficacy of these drug pairings.

August 2026: U.S. regulatory approval was granted for the combination treatment.
October 23, 2026: The study report was published.

Health Landscape

This research updates the treatment landscape for advanced gastroesophageal adenocarcinoma by benchmarking new combination regimens against standard care. It reflects an ongoing shift toward integrating multiple targeted agents to improve survival for patients with HER2-positive tumors.

Patients with HER2-positive gastroesophageal adenocarcinoma should discuss these survival findings with their oncology team to determine if this combination regimen is appropriate for their specific case. Understanding the role of HER2 status and available targeted agents is a key part of personal care planning.

The takeaway

This study highlights that combination regimens may offer survival advantages for those managing advanced HER2-positive gastroesophageal adenocarcinoma. Patients should focus on confirming their tumor's HER2 status and discussing how new combination therapies might fit into their current treatment path.